BioSpace News Archive

Generated cash flows from operating activities of $151 million in the first nine months of 2019, compared to $98 million during the same period in 2018

Concert Pharmaceuticals, Inc. reported financial results for the third quarter of 2019.

Reported positive data from Phase 2a clinical trial of mavorixafor in combination with axitinib in advanced clear cell renal cell carcinoma patients

AEGEA Medical announced the publication of the Post-Ablation Cavity Evaluation clinical study in the Journal of Minimally Invasive Gynecology.

AVEO Oncology and Biodesix, Inc. announced the initiation of the CyFi-2 study, a randomized Phase 2 clinical study evaluating ficlatuzumab, AVEO’s potent hepatocyte growth factor inhibitory antibody product candidate, in combination with high-dose cytarabine vs. high-dose cytarabine alone in patients with relapsed and refractory acute myeloid leukemia.

Exicure, Inc., a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid technology, reported financial results for the third quarter ended September 30, 2019 and provided an update on corporate progress.

First patient dosed in the global, pivotal, Phase 3 RAISE study of zilucoplan in gMG, with top-line results expected in early 2021

Remission maintenance and structural damage inhibition findings from the Phase IIIb AVERT-2 study highlight potential role for ORENCIA in de-escalation regimens in early moderate-to-severe rheumatoid arthritis (RA) patients positive for key biomarker for poor prognosis

Preclinical data on Bicycle® tumor-targeted immune cell agonists to be presented at SITC Annual Meeting on November 9, 2019

Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2020 operating results on Wednesday, November 13, 2019 before the open of the U.S. financial markets.